Jacques Van Dam
Papers
4
Total Citations
11
H-Index
2
About
Jacques Van Dam is a pioneering researcher at the intersection of biomedical engineering and gastroenterology, whose work is revolutionizing the oral delivery of biologic drugs. His primary research focus is the development of orally ingestible robotic pills that can safely and effectively deliver large-molecule therapeutics—such as antibodies and peptides—which have traditionally required painful injections due to digestion in the gastrointestinal tract. Van Dam’s landmark 2022 study demonstrated that a robotic pill could achieve bioavailability of antibodies comparable to parenteral administration in awake canines, a breakthrough that garnered immediate attention. He then led a first-in-human Phase 1 trial (2025) showing that the same platform could reliably deliver teriparatide, an osteoanabolic agent for osteoporosis, with high bioavailability in healthy volunteers—a finding with profound implications for the 70 million people projected to suffer from osteoporosis by 2030. His subsequent work extended this success to an ustekinumab biosimilar, further validating the platform’s versatility. With over 11 citations across his most-cited papers, Van Dam’s contributions are not only technically innovative but also clinically transformative, offering a needle-free future for patients requiring chronic biologic therapy.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3
- 4